- Home
- CUE vs EHGO Comparison
CUE vs EHGO Comparison
Compare CUE & EHGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- EHGO
- Stock Information
- Founded
- CUE 2014
- EHGO 2015
- Country
- CUE United States
- EHGO China
- Employees
- CUE N/A
- EHGO N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- EHGO
- Sector
- CUE Health Care
- EHGO
- Exchange
- CUE Nasdaq
- EHGO NYSE
- Market Cap
- CUE 48.0M
- EHGO N/A
- IPO Year
- CUE 2018
- EHGO 2024
- Fundamental
- Price
- CUE $0.68
- EHGO $0.88
- Analyst Decision
- CUE Strong Buy
- EHGO
- Analyst Count
- CUE 3
- EHGO 0
- Target Price
- CUE $3.00
- EHGO N/A
- AVG Volume (30 Days)
- CUE 313.6K
- EHGO 153.1K
- Earning Date
- CUE 08-13-2025
- EHGO 07-15-2025
- Dividend Yield
- CUE N/A
- EHGO N/A
- EPS Growth
- CUE N/A
- EHGO N/A
- EPS
- CUE N/A
- EHGO N/A
- Revenue
- CUE $7,991,000.00
- EHGO $15,393,105.00
- Revenue This Year
- CUE N/A
- EHGO N/A
- Revenue Next Year
- CUE $23.84
- EHGO N/A
- P/E Ratio
- CUE N/A
- EHGO N/A
- Revenue Growth
- CUE 13.83
- EHGO N/A
- 52 Week Low
- CUE $0.45
- EHGO $0.72
- 52 Week High
- CUE $1.99
- EHGO $5.50
- Technical
- Relative Strength Index (RSI)
- CUE 47.91
- EHGO N/A
- Support Level
- CUE $0.65
- EHGO N/A
- Resistance Level
- CUE $0.71
- EHGO N/A
- Average True Range (ATR)
- CUE 0.08
- EHGO 0.00
- MACD
- CUE 0.00
- EHGO 0.00
- Stochastic Oscillator
- CUE 38.62
- EHGO 0.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.